Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (https://www.amrindustryalliance.org/) (AMRIA)The Alliance
Visit Novartis Global Health on Twitter and Linkedin.
Friday, January 29, 2021 - 1:15am
CONTENT: Press Release
BASEL, SWITZERLAND, January 29, 2021 /3BL Media/ A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025.
Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year.
1 Despite the huge impact of MDT, governments, donors, civil society and the private sector will need to collaborate on deploying additional tools if the world is to get to zero leprosy.
Novartis, GSK team up for $3 6m genetic diversity research in Africa pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
ng
Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis (TB).
1
Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world. Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa. It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis. In alignment with our ongoing efforts to strengthen scientific capabilities in lower-resource settings, this project also provides opportunities